Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups A, C, W, Y) conjugate vaccine (tetanus toxoid carrier) + pneumococcal 13-valent conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the co-administration of the quadrivalent meningococcal conjugate vaccine (MenACWY-TT) and the 13-valent pneumococcal conjugate vaccine (PCV13). MenACWY-TT, marketed as MenQuadfi by Sanofi or Nimenrix by Pfizer, is a conjugate vaccine where capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y are covalently linked to a tetanus toxoid carrier protein. PCV13, marketed as Prevnar 13 by Pfizer, contains capsular polysaccharides from 13 serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) conjugated to a non-toxic mutant of diphtheria toxin (CRM197). The co-administration of these vaccines is common in pediatric and geriatric immunization schedules. Clinical trials have demonstrated that simultaneous administration at separate injection sites maintains the immunogenicity and safety profile of each individual vaccine, providing broad protection against invasive meningococcal and pneumococcal diseases.
- Other names
- meningococcal (groups A, C, W, Y) conjugate vaccine + pneumococcal 13-valent conjugate vaccineMenACWY-TT + PCV13
02
Targets
MenACWY (Neisseria meningitidis capsular polysaccharides serogroups A, C, W, and Y)TT (Tetanus toxoid)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on meningococcal (groups A, C, W, Y) conjugate vaccine (tetanus toxoid carrier) + pneumococcal 13-valent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups A, C, W, Y) conjugate vaccine (tetanus toxoid carrier) + pneumococcal 13-valent conjugate vaccine.